PATENT CLAIM ANALYSIS

Application Number: 16049390
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "464000"]

Abstract:
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Claim (Index 16):
The dosage form according to  claim 15  wherein the cationic cross-linking agent is selected from the group consisting of an alkali metal sulfate, chloride, borate, bromide, citrate, acetate or lactate or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate or lactate.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.18919
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11427438', '10190192', '11680432', '12716973', '14336753']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8194798583184907
- 35 USC 102 Novelty (BERT): 0.5831825134069837
- Combined Prediction Score: 0.79585012382734
- Mean Citation Score: 463.99081000000007
- Max Citation Score: 525.475
- Similarity Product: 395.6787396103144

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test